TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
Articul8 launches Bivia to bring domain-specific decision intelligence to enterprise AI agents